Celldex Therapeutics Inc
Suletud
SektorTervishoid
36.7 -2.99
Ülevaade
Aktsiahinna muutus
24h
Min
36.7
Max
37.39
Sissetulek | 5.2M -74M |
|---|---|
Müük | 7K 22K |
Aktsiakasum | -0.94 |
Kasumimarginaal | -334,104.545 |
Töötajad | 198 |
EBITDA | 5.2M -73M |
Järgmine tulemuste avaldamine | 6. nov 2026 |
|---|
Turukapital | 158M 3.1B |
|---|---|
Eelmine avamishind | 39.69 |
Eelmine sulgemishind | 36.7 |
Uudiste sentiment
By Acuity
50%
50%
126 / 339 Pingereas Healthcare
Celldex Therapeutics Inc Graafik
Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.
Seotud uudised
Võrdlus sarnastega
Hinnamuutus
Celldex Therapeutics Inc Prognoos
Sentiment
By Acuity
126 / 339 Pingereas Tervishoid
Uudiste sentiment
Neutral
Volatiilsus
Alla keskmise
Uudismaht (RCV)
Keskmine
Finantsandmed
Müügi- ja halduskulud
Tegevuskulud
Maksueelne kasum
Müük
Müügikulu
Brutokasum müügist
Intressikulud võla pealt
EBITDA
Ärikasum
$
Ettevõttest Celldex Therapeutics Inc
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.